How should fosfomycin be used for treatment and prophylaxis of recurrent cystitis?

Fosfomycin for Recurrent Cystitis

For acute treatment of recurrent cystitis episodes in women, use fosfomycin trometamol 3g as a single dose, which is a first-line option alongside nitrofurantoin and trimethoprim-sulfamethoxazole. However, fosfomycin should NOT be used as continuous prophylaxis for preventing recurrent UTIs—reserve antimicrobial prophylaxis only after non-antimicrobial measures have failed, and when used, employ other agents with established prophylactic regimens 1.

Treatment of Acute Episodes

First-Line Acute Treatment

Fosfomycin trometamol 3g single dose is recommended as first-line therapy for women with uncomplicated cystitis, including those with recurrent episodes 1. The 2024 EAU guidelines explicitly list it alongside nitrofurantoin and pivmecillinam as preferred initial options.

Key specifications from FDA labeling:

• Dosage: One 3g sachet mixed with water, taken as a single dose 2
• May be taken with or without food 2
• Critical limitation: Do not use repeated daily doses—this did not improve outcomes but increased adverse events 2

When to Use Fosfomycin for Acute Treatment

• Recommended only in women with uncomplicated cystitis 1
• Covers typical uropathogens including E. coli and Enterococcus faecalis 2
• Particularly valuable for its broad spectrum including VRE and ESBL-producing organisms 3
• Currently maintains low resistance rates 3
• Minimal collateral damage to microbiome 3

Important Limitations

Fosfomycin is NOT indicated for:

• Pyelonephritis or perinephric abscess 2
• If bacteriuria persists or reappears after treatment, select other therapeutic agents 2

Prophylaxis Strategy for Recurrent UTIs

The Algorithmic Approach

The 2024 EAU guidelines provide a clear hierarchy for preventing recurrent UTIs 1:

1. First: Non-antimicrobial measures (Strong recommendations)

   • Increase fluid intake in premenopausal women
   • Vaginal estrogen in postmenopausal women (Strong)
   • Immunoactive prophylaxis (Strong)
   • Methenamine hippurate in women without urinary tract abnormalities (Strong)

2. Second: Alternative non-antimicrobial options (Weak recommendations)

   • Cranberry products (though evidence is contradictory)
   • D-mannose (recent 2025 high-quality RCT showed NO benefit 3)
   • Probiotics for vaginal flora regeneration
   • Endovesical hyaluronic acid instillations (for refractory cases)

3. Third: Antimicrobial prophylaxis ONLY when non-antimicrobial interventions fail (Strong recommendation)

   • Use continuous or postcoital antimicrobial prophylaxis 1
   • Consider self-administered short-term therapy for compliant patients 1

Fosfomycin's Role in Prophylaxis

Fosfomycin is NOT recommended for standard prophylactic regimens in current guidelines 1, 3. The guidelines do not list fosfomycin among prophylactic antimicrobial options, and the FDA label explicitly warns against repeated daily dosing 2.

However, emerging research suggests potential:

• A 2026 retrospective study showed fosfomycin prophylaxis reduced UTI incidence by 85-95% in patients with urological comorbidities 4
• Older studies (2006-2007) in diabetic women showed efficacy with chronic fosfomycin therapy 5, 6
• These studies used various multi-dose regimens, not the single-dose approach

Critical caveat: This prophylactic use remains off-label and lacks guideline support. The FDA specifically states repeated daily doses did not improve outcomes and increased adverse events 2.

Practical Clinical Algorithm

For Acute Symptomatic Episodes:

1. Confirm diagnosis with urine culture in recurrent UTI patients 1
2. First-line options (choose based on local resistance patterns):
   • Fosfomycin 3g single dose
   • Nitrofurantoin 100mg BID × 5 days
   • TMP-SMX 160/800mg BID × 3 days (if local E. coli resistance <20%)
3. If symptoms don't improve in 2-3 days: Obtain culture and susceptibility, retreat with 7-day course of different agent 1, 2

For Prevention of Recurrences:

1. Start with behavioral/non-antimicrobial measures:
   • Increase fluid intake
   • Postmenopausal: vaginal estrogen (most effective)
   • Consider immunoactive prophylaxis or methenamine hippurate
2. If these fail after adequate trial:
   • Initiate continuous antimicrobial prophylaxis with established agents (NOT fosfomycin per current guidelines)
   • Alternative: postcoital prophylaxis
   • Alternative: patient-initiated short-course therapy

Common Pitfalls to Avoid

1. Don't use fosfomycin for repeated daily prophylaxis based on FDA warnings 2
2. Don't treat asymptomatic bacteriuria in women with recurrent UTI history—this increases symptomatic recurrence risk (47% vs 13%) 3
3. Don't use fosfomycin for pyelonephritis—it's only indicated for cystitis 2
4. Don't skip urine culture in recurrent UTI patients before treatment 1
5. Don't start antimicrobial prophylaxis first—exhaust non-antimicrobial options 1
6. Don't use fosfomycin in men for cystitis per guideline recommendations (men require 7-day treatment courses) 1

Adverse Effects and Monitoring

• Adverse events reported in 13.9% of prophylaxis patients, leading to discontinuation in only 3.4% 4
• Warn patients about potential diarrhea and C. difficile risk 2
• Patients should see symptom improvement within 2-3 days; if not, contact provider 2
• No routine post-treatment cultures needed if asymptomatic 1